펩타이드 치료제 시장 규모, 점유율, 동향 분석 보고서 : 종류별, 용도별, 제조업체 종류별, 투여 경로별, 합성 기술별, 지역별, 부문별 예측(2026-2033년)

Peptide Therapeutics Market Summary

The global peptide therapeutics market size was estimated at USD 140.86 billion in 2025 and is projected to reach USD 294.58 billion by 2033, growing at a CAGR of 8.73% from 2026 to 2033. The market is expanding steadily, supported by rising demand for targeted and high efficacy treatment options across major disease areas.

The increasing prevalence of metabolic disorders, particularly diabetes and obesity, continues to generate substantial demand for peptide-based drugs across developed and emerging markets. Strong commercial performance of GLP-1 receptor agonists has reinforced confidence in peptide platforms and accelerated research investments. Pharmaceutical companies are prioritizing peptide innovation to address unmet clinical needs with improved safety, selectivity, and tolerability profiles. Advances in peptide engineering have enhanced molecular stability, receptor specificity, and extended half-life, strengthening overall therapeutic performance. Growing physician preference for precision therapies is further elevating clinical adoption. Expanding biologics acceptance across healthcare systems is creating favorable conditions for peptide commercialization. These combined factors are contributing to sustained revenue expansion and long-term market growth.

Growth momentum is further supported by expanding applications in oncology, gastrointestinal disorders, cardiovascular conditions, and rare endocrine diseases. Peptide receptor targeting strategies are improving therapeutic precision and minimizing systemic toxicity in cancer treatment, while continuous innovation in long-acting formulations has reduced dosing frequency and improved patient adherence across chronic disease segments. Oral peptide delivery technologies are advancing through absorption enhancers and formulation optimization, increasing patient convenience and broadening eligible populations.

Companies are investing in differentiated pipeline candidates with dual or multi receptor activity to improve clinical outcomes, and strategic collaborations between biotechnology firms and major pharmaceutical companies are accelerating development timelines and strengthening commercialization capabilities. For instance, in September 2025, GlobeNewswire reported that once weekly injectable semaglutide was associated with a 23% reduced risk of major adverse cardiovascular events compared to dulaglutide in nearly 60,000 US Medicare patients aged 66 years or older, along with a 26% lower risk of death and a 25% lower risk of heart attack, stroke, hospitalization for unstable angina or heart failure and death from any cause, with results presented at the 2025 European Association for the Study of Diabetes Annual Meeting.

Manufacturing advancements are contributing to greater scalability, consistency, and cost efficiency across the peptide value chain. Improvements in solid phase peptide synthesis and hybrid production technologies are enhancing yield, purity, and batch reproducibility, while expanded capacity among contract development and manufacturing organizations is supporting global supply requirements. For instance, in May 2025, Pharma Manufacturing reported that Swiss based Bachem expanded multisite production capacities across Switzerland, the United States, and the United Kingdom, commenced construction of a new large scale facility known as Building K in Bubendorf, increased annual peptide production capacity at its Vista, California site to nearly one metric ton, doubled diagnostic peptide output at its St Helens site in the UK, and initiated concept design work for an additional facility in Sisseln, Switzerland, further strengthening global peptide manufacturing infrastructure.

Global Peptide Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global peptide therapeutics market report based on application, type, type of manufacturer, route of administration, synthesis technology, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Innovative
• Generic
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Metabolic Disorders
• Cancer
• Neurological Disorders
• Gastrointestinal Disorders
• Cardiovascular Disorders
• Pain
• Infectious Disease
• Renal Disorders
• Dermatological Disorders
• Respiratory Disorders
• Others
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Parenteral Route
• Oral Route
• Mucosal
• Pulmonary
• Others
• Synthesis Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Recombinant DNA Technology
• Solid-Phase Peptide Synthesis (SPPS)
• Hybrid
• Liquid-Phase Peptide Synthesis (LPPS)
• Others
• Type of Manufacturers Outlook (Revenue, USD Million, 2021 - 2033)
• Inhouse
• Outsourced
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Peptide Therapeutics Market Variables, Trends, & Scope

• 3.1. Parent Market Outlook
• 3.2. Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Increasing prevalence of cancer
      • 3.3.1.1.1. Cancer incidence data
    • 3.3.1.2. Technological advancements
    • 3.3.1.3. Presence of strong product pipeline
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Increasing complexity of peptides
    • 3.3.2.2. High cost of manufacturing equipment
• 3.4. Peptide Therapeutics Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape
• 3.5. Pipeline Analysis
  • 3.5.1. Phase 1
  • 3.5.2. Phase 2
  • 3.5.3. Phase 3

Chapter 4. Peptide Therapeutics Market: Type Estimates & Trend Analysis

• 4.1. Peptide Therapeutics Market: Type Segment Dashboard
• 4.2. Peptide Therapeutics Market: By Type Movement Analysis, 2025 & 2033 (USD Million)
• 4.3. Innovative
  • 4.3.1. Innovative Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Generic
  • 4.4.1. Generic Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Peptide Therapeutics Market: By Application Estimates & Trend Analysis

• 5.1. Peptide Therapeutics Market: Application Segment Dashboard
• 5.2. Peptide Therapeutics Market: By Application Movement Analysis, 2025 & 2033 (USD Million)
• 5.3. Metabolic Disorders
  • 5.3.1. Metabolic Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Cancer
  • 5.4.1. Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Neurological Disorders
  • 5.5.1. Neurological Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Gastrointestinal Disorders
  • 5.6.1. Gastrointestinal Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Cardiovascular Disorders
  • 5.7.1. Cardiovascular Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Pain
  • 5.8.1. Pain Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Infectious Disease
  • 5.9.1. Infectious Disease Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.10. Renal Disorders
  • 5.10.1. Renal Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.11. Dermatological Disorders
  • 5.11.1. Dermatological Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.12. Respiratory Disorders
  • 5.12.1. Respiratory Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.13. Others
  • 5.13.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Peptide Therapeutics Market: Type of Manufacturer Estimates & Trend Analysis

• 6.1. Peptide Therapeutics Market: Type of Manufacturer Segment Dashboard
• 6.2. Peptide Therapeutics Market: By Type of Manufacturer Movement Analysis, 2025 & 2033 (USD Million)
• 6.3. Inhouse
  • 6.3.1. Inhouse Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Outsourced
  • 6.4.1. Outsourced Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Peptide Therapeutics Market: Synthesis Technology Estimates & Trend Analysis

• 7.1. Peptide Therapeutics Market: Synthesis Technology Segment Dashboard
• 7.2. Peptide Therapeutics Market: Synthesis Technology Movement Analysis, 2025 & 2033 (USD Million)
• 7.3. Recombinant DNA Technology
  • 7.3.1. Recombinant DNA Technology Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Solid-Phase Peptide Synthesis (SPPS)
  • 7.4.1. Solid-Phase Peptide Synthesis (SPPS) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Hybrid
  • 7.5.1. Hybrid Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Liquid-Phase Peptide Synthesis (LPPS)
  • 7.6.1. Liquid-Phase Peptide Synthesis (LPPS) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Peptide Therapeutics Market: Route of Administration Estimates & Trend Analysis

• 8.1. Peptide Therapeutics Market: Route of Administration Segment Dashboard
• 8.2. Peptide Therapeutics Market: Route of Administration Movement Analysis, 2025 & 2033 (USD Million)
• 8.3. Parenteral Route
  • 8.3.1. Parenteral Route Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Oral Route
  • 8.4.1. Oral Route Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Mucosal
  • 8.5.1. Mucosal Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Pulmonary
  • 8.6.1. Pulmonary Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Others
  • 8.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Peptide Therapeutics Market: Regional Estimates & Trend Analysis

• 9.1. Peptide Therapeutics Market Share, By Region, 2025 & 2033 (USD Million)
• 9.2. North America
  • 9.2.1. North America Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key Country Dynamics
    • 9.2.2.2. Target Disease Prevalence
    • 9.2.2.3. Regulatory Framework
    • 9.2.2.4. Reimbursement Framework
    • 9.2.2.5. U.S. Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.2.3. Canada
    • 9.2.3.1. Key Country Dynamics
    • 9.2.3.2. Target Disease Prevalence
    • 9.2.3.3. Regulatory Framework
    • 9.2.3.4. Reimbursement Framework
    • 9.2.3.5. Canada Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.2.4. Mexico
    • 9.2.4.1. Key Country Dynamics
    • 9.2.4.2. Target Disease Prevalence
    • 9.2.4.3. Regulatory Framework
    • 9.2.4.4. Reimbursement Framework
    • 9.2.4.5. Mexico Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.3. Europe
  • 9.3.1. Europe Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.2. UK
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Target Disease Prevalence
    • 9.3.2.3. Regulatory Framework
    • 9.3.2.4. Reimbursement Framework
    • 9.3.2.5. Uk Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.3. Germany
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Target Disease Prevalence
    • 9.3.3.3. Regulatory Framework
    • 9.3.3.4. Reimbursement Framework
    • 9.3.3.5. Germany Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.4. France
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Target Disease Prevalence
    • 9.3.4.3. Regulatory Framework
    • 9.3.4.4. Reimbursement Framework
    • 9.3.4.5. France Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.5. Italy
    • 9.3.5.1. Key Country Dynamics
    • 9.3.5.2. Target Disease Prevalence
    • 9.3.5.3. Regulatory Framework
    • 9.3.5.4. Reimbursement Framework
    • 9.3.5.5. Italy Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.6. Spain
    • 9.3.6.1. Key Country Dynamics
    • 9.3.6.2. Target Disease Prevalence
    • 9.3.6.3. Regulatory Framework
    • 9.3.6.4. Reimbursement Framework
    • 9.3.6.5. Spain Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.7. Denmark
    • 9.3.7.1. Key Country Dynamics
    • 9.3.7.2. Target Disease Prevalence
    • 9.3.7.3. Regulatory Framework
    • 9.3.7.4. Reimbursement Framework
    • 9.3.7.5. Denmark Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.8. Sweden
    • 9.3.8.1. Key Country Dynamics
    • 9.3.8.2. Target Disease Prevalence
    • 9.3.8.3. Regulatory Framework
    • 9.3.8.4. Reimbursement Framework
    • 9.3.8.5. Sweden Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.9. Norway
    • 9.3.9.1. Key Country Dynamics
    • 9.3.9.2. Target Disease Prevalence
    • 9.3.9.3. Regulatory Framework
    • 9.3.9.4. Reimbursement Framework
    • 9.3.9.5. Norway Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.2. Japan
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Target Disease Prevalence
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. Reimbursement Framework
    • 9.4.2.5. Japan Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.3. China
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Target Disease Prevalence
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Reimbursement Framework
    • 9.4.3.5. China Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.4. India
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Target Disease Prevalence
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. Reimbursement Framework
    • 9.4.4.5. India Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.5. Australia
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Target Disease Prevalence
    • 9.4.5.3. Regulatory Framework
    • 9.4.5.4. Reimbursement Framework
    • 9.4.5.5. Australia Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.6. South Korea
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Target Disease Prevalence
    • 9.4.6.3. Regulatory Framework
    • 9.4.6.4. Reimbursement Framework
    • 9.4.6.5. South Korea Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.7. Thailand
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Target Disease Prevalence
    • 9.4.7.3. Regulatory Framework
    • 9.4.7.4. Reimbursement Framework
    • 9.4.7.5. Thailand Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5. Latin America
  • 9.5.1. Latin America Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Target Disease Prevalence
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Reimbursement Framework
    • 9.5.2.5. Brazil Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.3. Argentina
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Target Disease Prevalence
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. Reimbursement Framework
    • 9.5.3.5. Argentina Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6. Middle East & Africa
  • 9.6.1. Middle East & Africa Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.2. South Africa
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Target Disease Prevalence
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Reimbursement Framework
    • 9.6.2.5. South Africa Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Target Disease Prevalence
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Reimbursement Framework
    • 9.6.3.5. Saudi Arabia Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.4. UAE
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Target Disease Prevalence
    • 9.6.4.3. Regulatory Framework
    • 9.6.4.4. Reimbursement Framework
    • 9.6.4.5. UAE Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.5. Kuwait
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Target Disease Prevalence
    • 9.6.5.3. Regulatory Framework
    • 9.6.5.4. Reimbursement Framework
    • 9.6.5.5. Kuwait Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis by Key Market Participants
• 10.2. Company Categorization
• 10.3. Participant Overview
• 10.4. Financial Performance
• 10.5. Product Bench Marking
• 10.6. Company Market Share Analysis, 2025
• 10.7. Company Profiles
  • 10.7.1. Eli Lilly and Company
    • 10.7.1.1. Participant's Overview
    • 10.7.1.2. Financial Performance
    • 10.7.1.3. Product Benchmarking
    • 10.7.1.4. Recent Developments/ Strategic Initiatives
  • 10.7.2. Pfizer Inc.
    • 10.7.2.1. Participant's Overview
    • 10.7.2.2. Financial Performance
    • 10.7.2.3. Product Benchmarking
    • 10.7.2.4. Recent Developments/ Strategic Initiatives
  • 10.7.3. Amgen Inc.
    • 10.7.3.1. Participant's Overview
    • 10.7.3.2. Financial Performance
    • 10.7.3.3. Product Benchmarking
    • 10.7.3.4. Recent Developments/ Strategic Initiatives
  • 10.7.4. Takeda Pharmaceutical Company Limited
    • 10.7.4.1. Participant's Overview
    • 10.7.4.2. Financial Performance
    • 10.7.4.3. Product Benchmarking
    • 10.7.4.4. Recent Developments/ Strategic Initiatives
  • 10.7.5. AstraZeneca
    • 10.7.5.1. Participant's Overview
    • 10.7.5.2. Financial Performance
    • 10.7.5.3. Product Benchmarking
    • 10.7.5.4. Recent Developments/ Strategic Initiatives
  • 10.7.6. Teva Pharmaceutical Industries Ltd.
    • 10.7.6.1. Participant's Overview
    • 10.7.6.2. Financial Performance
    • 10.7.6.3. Product Benchmarking
    • 10.7.6.4. Recent Developments/ Strategic Initiatives
  • 10.7.7. Sanofi
    • 10.7.7.1. Participant's Overview
    • 10.7.7.2. Financial Performance
    • 10.7.7.3. Product Benchmarking
    • 10.7.7.4. Recent Developments/ Strategic Initiatives
  • 10.7.8. F. Hoffmann-La Roche Ltd
    • 10.7.8.1. Participant's Overview
    • 10.7.8.2. Financial Performance
    • 10.7.8.3. Product Benchmarking
    • 10.7.8.4. Recent Developments/ Strategic Initiatives
  • 10.7.9. Novartis AG
    • 10.7.9.1. Participant's Overview
    • 10.7.9.2. Financial Performance
    • 10.7.9.3. Product Benchmarking
    • 10.7.9.4. Recent Developments/ Strategic Initiatives
  • 10.7.10. Novo Nordisk A/S
    • 10.7.10.1. Participant's Overview
    • 10.7.10.2. Financial Performance
    • 10.7.10.3. Product Benchmarking
    • 10.7.10.4. Recent Developments/ Strategic Initiatives
  • 10.7.11. GSK plc
    • 10.7.11.1. Participant's Overview
    • 10.7.11.2. Financial Performance
    • 10.7.11.3. Product Benchmarking
    • 10.7.11.4. Recent Developments/ Strategic Initiatives
  • 10.7.12. Ironwood Pharmaceuticals, Inc.
    • 10.7.12.1. Participant's Overview
    • 10.7.12.2. Financial Performance
    • 10.7.12.3. Product Benchmarking
    • 10.7.12.4. Recent Developments/ Strategic Initiatives
  • 10.7.13. Radius Health, Inc. (Subsidiary of Gurnet Point Capital and Patient Square Capital)
    • 10.7.13.1. Participant's Overview
    • 10.7.13.2. Financial Performance
    • 10.7.13.3. Product Benchmarking
    • 10.7.13.4. Recent Developments/ Strategic Initiatives
  • 10.7.14. Ipsen Pharma
    • 10.7.14.1. Participant's Overview
    • 10.7.14.2. Financial Performance
    • 10.7.14.3. Product Benchmarking
    • 10.7.14.4. Recent Developments/ Strategic Initiatives

Chapter 11. Conclusion